RADX FY2026 EPS Raised by Brookline Capital Management

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Investment analysts at Brookline Capital Management upped their FY2026 earnings per share estimates for shares of Radiopharm Theranostics in a research report issued on Wednesday, October 22nd. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($2.25) per share for the year, up from their prior estimate of ($4.81). Brookline Capital Management has a “Buy” rating and a $18.00 price target on the stock. Brookline Capital Management also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($2.38) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $15.00.

Radiopharm Theranostics Price Performance

NASDAQ RADX opened at $5.33 on Monday. The stock’s 50 day moving average is $6.13 and its 200 day moving average is $5.09. Radiopharm Theranostics has a 12 month low of $3.50 and a 12 month high of $50.82.

Institutional Trading of Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. acquired a new position in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned about 0.10% of Radiopharm Theranostics at the end of the most recent reporting period.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.